



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

21 June 2019
EMA/CVMP/319271/2019
Committee for Medicinal Products for Veterinary Use

Summary of opinion¹ (post-authorisation)

Advocate

International non-proprietary name (INN): imidacloprid / moxidectin

On 20 June 2019, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion², recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Advocate. The marketing authorisation holder for this veterinary medicinal product is Bayer Animal Health GmbH.

Advocate is currently authorised as spot-on solution for cats, ferrets and dogs. The variation concerns the addition of new therapeutic indications in cats: the prevention and treatment of *Aelurostrongylus abstrusus* and the treatment of *Thelazia callipaeda*; also, the product information is amended with regard to pharmacological properties of moxidectin in cats.

Detailed conditions for the use of this product are described in the updated summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

¹ Summaries of opinion are published without prejudice to the Commission Decision.

² Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Temporary visiting address Spark building • Orlyplein 24 • 1043 DP Amsterdam • The Netherlands

For deliveries refer to www.ema.europa.eu/how-to-find-us

Send us a question via www.ema.europa.eu/contacts **Telephone** +31(0)88 781 6000

An agency of the European Union

